FDA Clear On Supplement Ingredient Petitions, But Still Fuzzy On Sec. 912
This article was originally published in The Pink Sheet Daily
Executive Summary
No regulatory changes are needed to help firms introduce ingredients that were part of INDs before being removed from consideration as drug ingredients, FDA Assistant Commissioner Ireland tells members of Congress. But FDA still has no answer on introducing ingredients studied in clinical trials but not in INDs.
You may also be interested in...
FDA Guidance Makes Vinpocetine Compliant Despite Ban Proposal – NPA
NPA CEO Daniel Fabricant says some vinpocetine product marketers don't realize the ingredient's status as an active moiety of a botanical long used in the food supply, a knowledge gap obscures that FDA is using an extra-regulatory procedure to remove vinpocetine.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: